Skip to main content
. Author manuscript; available in PMC: 2013 May 15.
Published in final edited form as: J Immunol. 2012 Apr 18;188(10):4913–4920. doi: 10.4049/jimmunol.1103668

Figure 2. DNP treatment induces splenic DCs and Tregs to acquire regulatory phenotypes via IDO.

Figure 2

A–E. Graded numbers of MACS-enriched splenic CD11c+ DCs from untreated B6 (A) or pDNA/PEI-treated (i/v, 24 hrs.) mice were cultured with responder OT-1 T cells and OVA peptide. Parallel cultures contained IDO inhibitor (1MT, 200 µM). F–I. Graded numbers of MACs-enriched CD4+CD25+ Tregs were cultured with A1 T cells & APCs and H-Y peptide. Parallel cultures contained a cocktail of anti-PD-1 and anti-PD-L1/L2 blocking mAbs. T cell proliferation was assessed by measuring thymidine incorporation (72 hrs). Data are the means (+/− 1sd) from triplicate cultures. Asterisks highlight significant IDO-dependent suppression mediated by DCs or Tregs. Data are representative of experiments performed with 2 or more DNP-treated mice.